Seasoned Management Team with Strong Experience in Glaucoma
Milestones achieved:
🏆 Best Project – Keiretsu Forum (Barcelona, May 2025) Awarded Best Project at one of the world’s most prestigious investment networks. https://www.linkedin.com/feed/update/urn:li:activity:7333162173956775938
🔖 ENISA Seal as an Innovative Company (2025) Official distinction recognizing Telara Pharma’s technological and innovative excellence. https://www.linkedin.com/feed/update/urn:li:activity:7333085018698727425
🏅 Winners of the Biotechnology & Lifesciences Awards 2025 – GHP Magazine
Ophthalmology Innovators of the Year 2025
Best Cilastatin Development Company 2025 https://www.linkedin.com/feed/update/urn:li:activity:7325525651673739266
🌟 Top 5 at the Innovator’s Pitch Challenge – RESI Europe (April 2025) Our glaucoma project was recognized among the top five innovations at the event organized by Life Science Nation and Biocat. https://www.linkedin.com/feed/update/urn:li:activity:7320829425057472512
🌐 Finalists in the EIT Health Supernovas Program (2024) Selected among the top European women-led innovation projects.
🔬 Nephroprotection patents licensed to Arch Biopartners (2021)
Telara licensed its nephroprotection patents to the Canadian pharmaceutical company Arch Biopartners.
In 2025, cilastatin entered the Phase II PONTIAC clinical trial, targeting acute kidney injury caused by drug-induced toxicity, marking significant progress toward clinical application.
The team
The Telara team is an agile and experienced management team with strong expertise in drug development.
We have a scientific advisory board and key opinion leaders with extensive experience in ophthalmology who have already brought ophthalmic drugs to market.
Dr. Teresa Tarragó
The CEO has extensive experience in managing biotechnology companies and a strong track record in preclinical and clinical regulatory development in neuroprotection. She is a serial entrepreneur with one successful exit.
The co‑founder and CSO, Dr. Alberto Lázaro, is a renowned researcher in the field of acute kidney injury, multi‑organ failure, inflammation, cell death, and in the development of new therapeutic alternatives for neuroprotection.
The CMO, Alfonso Antón, is a leading ophthalmologist and KOL, serving as Director of the Glaucoma Unit at the Institut Català de Retina. He has extensive experience in clinical trials of new neuroprotective drugs for the treatment of glaucoma.
